Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults: A controlled clinical trial.

ABSTRACT:

Objective

To determine whether treatment with escitalopram compared with placebo would lower CSF β-amyloid 42 (Aβ₄₂) levels.

Rationale

Serotonin signaling suppresses Aβ₄₂ in animal models of Alzheimer disease (AD) and young healthy humans. In a prospective study in older adults, we examined dose and treatment duration effects of escitalopram.

Methods

Using lumbar punctures to sample CSF levels before and after a course of escitalopram treatment, cognitively normal older adults (n = 114) were assigned to placebo, 20 mg escitalopram × 2 weeks, 20 mg escitalopram × 8 weeks, or 30 mg escitalopram × 8 weeks; CSF sampled pretreatment and posttreatment and within-subject percent change in Aβ₄₂ was used as the primary outcome in subsequent ana

SUBMITTER: Sheline YI 

PROVIDER: S-EPMC7713735 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature